The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Lautz, Timothy B ^a,b   Jie, Chunfa ^b   Clark, Sandra ^b   Naiditch, Jessica A ^a,b   Jafari, Nadereh ^b   Qiu, Yi Yong ^b   Zheng, Xin ^b   Chu, Fei ^b   Madonna, Mary Beth ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; HYPOXIA INDUCIBLE FACTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL LINE; CELL METABOLISM; CELL STRAIN SK N BE; CELL STRAIN SK N SH; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; NEUROBLASTOMA; PHENOTYPE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; NEUROBLASTOMA;

EID: 84864048360     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040816     Document Type: Article

References (33)

1. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, et al. (2006) High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 24: 2891-6.
2. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, et al. (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 27: 1007-13.
3. Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, et al. (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28: 2625-34.
4. US National Institute of Health. Clinical Trials. Available:http://clinicaltrials.gov/ct2/show/NCT00499616. Accessed 2011 March 14.
5. Haber M, Bordow SB, Haber PS, Marshall GM, Stewart BW, et al. (1997) The prognostic value of MDR1 gene expression in primary untreated neuroblastoma. Eur J Cancer 33: 2031-6.
6. Haber M, Smith J, Bordow SB, Flemming C, Cohn SL, et al. (2006) Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 24: 1546-53.
7. Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N, (2010) Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther 9: 3289-301.
8. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, et al. (2008) Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99: 376-84.
9. Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I, (2009) Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 15: 436-47.
10. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, et al. (2010) Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol 28: 3623-9.
11. Du P, Kibbe WA, Lin SM, (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-8.
12. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-93.
13. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
14. Smyth GK, Ritchie M, Thorne N, Wettenhal J. Limma: Linear Models for Microarray Data User's Guide. Available:http://www.bioconductor.org/packages/release/bioc/html/limma.html. Accessed 2012 June 27.
15. Alexa A, Rahnenfuhrer J. Gene set enrichment analysis with topGO. Available:http://www.bioconductor.org/packages/release/bioc/html/topGO.html. Accessed 2012 June 27.
16. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, et al. (2001) The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61: 3591-4.
17. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, et al. (1999) Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 59: 4392-9.
18. Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, et al. (2009) Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 53: 505-8.
19. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, et al. (2007) Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 99: 1107-19.
20. Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, et al. (2009) Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15: 91-9.
21. Gillet JP, Gottesman MM, (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76.
22. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, et al. (2007) Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 17: 647-51.
23. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, et al. (2009) Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 8: 1596-605.
24. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, et al. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62: 3387-94.
25. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, et al. (2009) Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 69: 9056-64.
26. Bhatt RS, Landis DM, Zimmer M, Torregrossa J, Chen S, et al. (2008) Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int 102: 358-63.
27. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, et al. (2005) Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675-86.
28. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, et al. (2009) Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 324: 1289-93.
29. Witte I, Altenhofer S, Wilgenbus P, Amort J, Clement AM, et al. (2011) Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. Cell Death Dis 2: e112.
30. Keenan J, Murphy L, Henry M, Meleady P, Clynes M, (2009) Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 9: 1556-66.
31. Zhao LY, Niu Y, Santiago A, Liu J, Albert SH, et al. (2006) An EBF3-mediated transcriptional program that induces cell cycle arrest and apoptosis. Cancer Res 66: 9445-52.
32. Montopoli M, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, et al. (2011) "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. Curr Cancer Drug Targets 11: 226-35.
33. Temmink OH, Bijnsdorp IV, Prins HJ, Losekoot N, Adema AD, et al. (2010) Trifluorothymidine resistance is associated with decreased thymidine kinase and equilibrative nucleoside transporter expression or increased secretory phospholipase A2. Mol Cancer Ther 9: 1047-57.